PR
TGTX icon

PSP Research’s TG Therapeutics TGTX Stock Holding History

PSP Research’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$549K Sell
10,000
-3,000
-23% -$123K 0.29% 12
2026
Q1 		$432K Sell
13,000
-4,807
-27% -$143K 0.31% 43
2025
Q4 		$531K Buy
+17,807
New +$582K 0.46% 40

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

PSP Research's TGTX Position: Q2 2026 in Review

PSP Research reduced its TG Therapeutics (TGTX) stake by 23% in Q2 2026, selling an estimated $123K and leaving 10,000 shares worth $549K. The position accounts for 0.29% of the portfolio, ranked #12.

PSP Research first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • PSP Research held 10,000 shares of TG Therapeutics worth $549K as of Q2 2026.
  • PSP Research sold 3,000 TG Therapeutics shares in Q2 2026, an estimated $123K.
  • TG Therapeutics made up 0.29% of PSP Research's portfolio in Q2 2026, its #12 holding.
  • PSP Research first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.